8-K: Passage Bio Presents Promising Preclinical and Clinical Data for PBFT02 Gene Therapy in FTD-GRN

Passage Bio announced positive preclinical and interim clinical data for its PBFT02 gene therapy, showing significant increases in progranulin levels and a favorable safety profile in patients with frontotemporal dementia with GRN mutations (FTD-GRN).

Summary

• Passage Bio presented preclinical and interim clinical data for PBFT02, a gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), at the European Society of Gene & Cell Therapy 31st Annual Congress.
• Preclinical studies demonstrated that an AAV1 vector achieved superior human progranulin (PGRN) levels in the cerebrospinal fluid (CSF) compared to AAV5 and AAVhu68.
• In Grn knockout mice, PBFT02 improved lysosomal histopathology and reduced neuroinflammation.
• Non-human primate (NHP) studies showed widespread vector distribution throughout the nervous system after intra-cisterna magna (ICM) administration.
• Interim clinical data from the upliFT-D trial showed that PBFT02 was generally well-tolerated at Dose 1 and led to consistent, durable increases in CSF progranulin levels in all treated patients, with elevated levels sustained up to 12 months post-administration.
• The company is continuing to assess Dose 1 in Cohort 2 of the upliFT-D trial.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical and interim clinical data, suggesting a promising future for PBFT02. The safety profile appears favorable, and the efficacy data is encouraging. However, there are still risks associated with clinical trials and regulatory approvals.

Positives

• The AAV1 vector demonstrated superior progranulin levels in preclinical studies compared to other vectors.
• PBFT02 showed positive effects on lysosomal function and neuroinflammation in preclinical models.
• The gene therapy achieved broad distribution throughout the nervous system in non-human primates.
• Interim clinical data indicates a favorable safety profile for PBFT02 at Dose 1.
• The therapy resulted in consistent and durable increases in CSF progranulin levels in treated patients.
• The revised steroid regimen in the upliFT-D trial appears to have improved the safety profile of the treatment.

Negatives

• An immune response to the human protein in NHPs attenuated PGRN levels after day 14, although this is not expected to be relevant in FTD-GRN patients.
• One patient in the upliFT-D trial experienced two severe adverse events (SAEs) before the revised steroid regimen was implemented.

Risks

• The company's ability to develop and obtain regulatory approval for PBFT02 is subject to risks.
• Clinical trial results may not be replicated in subsequent trials.
• There are risks associated with clinical trials, including the possibility of unexpected concerns arising from additional data or analysis.
• The company is dependent on collaborators and third parties for the development and manufacture of product candidates.
• There are risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio is committed to advancing PBFT02 in FTD and exploring its therapeutic potential in additional neurodegenerative diseases that could benefit from elevated progranulin levels. The company is continuing to assess Dose 1 in Cohort 2 of the upliFT-D trial.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that the strong preclinical results gave them confidence in choosing the AAV1 vector and ICM administration.
• Will Chou also noted that it is encouraging to see preclinical findings translate into the clinic, with interim PBFT02 data demonstrating a well-tolerated safety profile and consistent, durable increases in CSF progranulin levels.

Industry Context

This announcement is significant in the context of the broader gene therapy field, particularly for neurodegenerative diseases. The use of AAV1 and ICM administration represents a differentiated approach. The positive interim clinical data suggests a potential advancement in the treatment of FTD-GRN, a disease with no approved disease-modifying therapies.

Comparison to Industry Standards

• The use of AAV1 for gene delivery is notable as it has shown superior results compared to AAV5 and AAVhu68 in this study, which is a key differentiator.
• The ICM administration route is less common than intravenous delivery, and the data suggests it provides better distribution of the gene therapy in the CNS.
• The sustained increase in CSF progranulin levels for up to 12 months is a positive indicator compared to other gene therapies that may have shorter durations of effect.
• The safety profile of PBFT02, particularly with the revised steroid regimen, appears to be competitive with other gene therapy trials.

Stakeholder Impact

• Shareholders may view the positive data as a positive sign for the company's future.
• Patients and families affected by FTD-GRN may have increased hope for a potential treatment.
• Employees of Passage Bio may be motivated by the positive results.
• The results may impact the company's relationships with collaborators and partners.

Next Steps

• Passage Bio will continue to assess Dose 1 in Cohort 2 of the upliFT-D clinical trial.
• The company will explore the therapeutic potential of PBFT02 in additional neurodegenerative diseases that could benefit from elevated progranulin levels.

Key Dates

Keywords

PBFT02, Gene Therapy, Frontotemporal Dementia, FTD-GRN, Progranulin, AAV1, Neurodegenerative Diseases, Clinical Trial, UpliFT-D, CSF, Intra-cisterna magna, PGRN